Navigation Links
Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
Date:5/1/2013

PRINCETON, N.J., May 1, 2013 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported results for its first quarter ended March 31, 2013.  Net revenue was $580 million, representing 9.3% growth from the first quarter of 2012.  On a GAAP basis, the company reported earnings of $0.86 per diluted share in the first quarter.  Excluding a gain on the sale of our investment in BioClinica, Inc. of $15.7 million and restructuring costs totaling $6.2 million, the company reported earnings per diluted share of $0.75, up 24.7% over the first quarter of 2012. 

"Significantly higher kit volumes in central laboratories and continued strength in clinical development drove better-than-expected consolidated results in the first quarter, including revenue growth of 9.3%, pro forma operating margin of 9.4%, and pro forma EPS of $0.75," said Joe Herring, Chairman and Chief Executive Officer. "We continue to win in the marketplace as evidenced by our adjusted net orders of $716 million in the quarter, representing an adjusted net book-to-bill of 1.23 to 1.

"Late-Stage Development first quarter revenues grew 16.8% year-on-year to $373 million. Central laboratories and clinical development grew 20% and 18%, respectively, which more than offset a decline in our market access services. Late-Stage Development pro forma operating margins were above our expectations at 22.8%, primarily due to increased volume in our central laboratory.

"In Early Development, results declined from the fourth quarter level as forecasted, with sequential growth in clinical pharmacology, research products, and nutritional chemistry being more than offset by a decline in toxicology and discovery support services. Revenue of $207 million declined 2.1% from the first quarter of last year while pro forma operating margin of 9.7% grew 440 basis points year-on-year, largely a result of our 2
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
7. Covance To Present At The Leerink Swann Global Healthcare Conference
8. Covance To Present At The Citi 2013 Global Healthcare Conference
9. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
10. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
11. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014   Coqui RadioPharmaceuticals Corp. , ... U.S. commercial producer of Molybdenum-99 (Mo-99), is proud to ... INVAP to design its Medical Isotope Production Facility ... is the parent isotope of Technetium-99, which is used ... 2012, Congress passed legislation making it a national priority ...
(Date:11/21/2014)... --  Wellcentive , the industry leader in end-to-end ... today being named one of the four finalists ...  Sponsored by Intel, the world leader in computing ... companies developing leading-edge technology and unique approaches to ... Wellcentive,s Mason Beard , senior vice ...
(Date:11/21/2014)... 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... of $80,000,000 aggregate principal amount of 5.25% Convertible Senior ... offering within the United States . ... pursuant to Rule 144A under the Securities Act of ... granted the initial purchasers an option to purchase up ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... SWANTON, Vt ., May 7 This May, AllerAir ... their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness tips ... www.allerair.com .  Additionally, their blogs and articles ...
... A post-hoc analysis of a Phase 3 safety study ... a lower incidence of nausea, vomiting and constipation when compared ... moderate to severe low-back or osteoarthritis pain.  These data will ... Annual Scientific Meeting of the American Pain Society (APS), and ...
Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 2Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 4Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 5Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 6Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 7Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 8Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 9
(Date:11/23/2014)... 2014 SWAccessControl.com's high quality access control ... the company has announced its new collection of power ... these high quality power suppliers. All the new models ... special offer lasts until Dec. 20, 2014. , SWAccessControl.com ... have been supporting it for a long time. It ...
(Date:11/23/2014)... Falls Church, VA (PRWEB) November 23, 2014 ... and TV Have in Common, **FDAnews On-Demand Webinar**, Dec. ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional ... ads. , Now they're looking at websites, ... , Mark the calendar for Thursday, Dec. 11, for ...
(Date:11/22/2014)... Greenville, SC (PRWEB) November 23, 2014 ... back to their communities. AlignLife experience rapid growth in ... upon a very unique opportunity. AlignLife of Simpsonville ... area AlignLife offices for their first annual Toy Drive. ... local charity they would support with this year's toy ...
(Date:11/22/2014)... A classic black prom dress will never go out of ... unveiled its new items of black prom gowns . ... big discount, up to 70% off. People throughout the world ... prom dresses, made with the best materials, can make wearers ... customers, the company provides these beautiful outfits in a huge ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Due to my ... an inventor, from Gurnee, Ill. “While using the ice grip ... and I thought there needed to be a safer way ... the SPIKE BLOCK. , The SPIKE BLOCK offers added safety ... it would help to reduce injuries and damage associated with ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... The Cosmetic Bootcamp, LLC,announces that its annual marketing and ... will begin on Dec. 11, 2008. Despite a ... sponsorship.,According to program chair, Kenneth Beer MD, "We are ... for specialists both by the specialists,and industry." Dr. ...
... resource the necessary information to make an informed decision when ... , , LYNDHURST, N.J., Dec. ... city,s best otolaryngologist (and figuring out what an otolaryngologist is), ... if you,re not an MD, a DO or are certified ...
... Phase II Cancer Trials and the Company,s Other Clinical Programs All ... - Significant Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral ... - Company Enters into Loan Agreement for Up to ... TUSTIN, Calif., Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: ...
... PetFit(TM) Challenge Participant Shows Remarkable Quick Weight Loss Improvement , ... On January 20, Zeb, a 104 pound, 7-year-old, Labrador ... Hill,s PetFit(TM) Challenge participants. At Zeb,s recheck on ... lost 22 pounds and was now at 82 pounds. Dr. ...
... dry skin... much of the time with poor results. During Winter, ... the skin. , ... Denver, CO. (PRWEB) December 10, 2008 -- Winter ... across the country suffering from dry skin problems. According to estimates ...
... Global Med Technologies(R), Inc.,("Global Med" or the "Company") (OTC ... today announced that on,Tuesday, December 9, 2008, its board ... LLC ("VPC") whereby VPC proposed to acquire a,majority share ... proposal received is,as follows: , , ...
Cached Medicine News:Health News:Vitals Launches Free eBook to Help Consumers Find 'Dr. Right' 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Video: Combined Veterinary and Pet Owner Efforts Help Pet Lose Big 2Health News:Video: Combined Veterinary and Pet Owner Efforts Help Pet Lose Big 3Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 2Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 3Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 2Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 3Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 4
The Fluoroskan Ascent FL is equipped with both fluorometric and luminometric measurement technologies, providing a full coverage for fluorometric, glow and flash luminometric applications even in the...
FlexStationII offers the highest level of flexibility in developing functional cellular assays and analyzing real time kinetic data....
... The C&L Dye Fluorometer utilizes unique ... the illumination and detection optics. The filter ... emission for numerous types of applications. With ... settle on measuring one or two wavelengths. ...
... The Modulus™ is a ... designed to give you ... fluorescence, luminescence, and absorbance. ... dedicated fluorometer, dedicated luminometer, ...
Medicine Products: